1[1]Shen DH, Ng Ty, Khoo US,et al. Pseudomyxoma peritoneia heterogenous disease [J]. Int J Gynaecol Obstet, 1998; 62(2) ∶ 173
2[2]Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis [J]. Cancer, 2001; 92(1) ∶ 85
3[3]Kishimoto S, Kameyama M, Kodama K, et al. A case report of malignant pseudomyxoma peritonei treated by a new modality of intraperitoneal chemo-hyperthermia [J]. Gan to Kagaku Ryoho, 1993; 20(11) ∶ 1703
4[4]Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach [J]. Ann Surg, 1994; 219(2) ∶ 112
5[5]Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome [J]. Eur J Surg Oncol, 2001; 27(3) ∶ 239
7[29]Bryant J,Clegg AJ,Sidhu MK,Brodin H,Royle P,Davidson P.Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei.Health Technol Assess 2004; 8:iii,1-54
8[30]Gomez Portilla A,Deraco M,Sugarbaker PH.Clinical pathway for peritoneal carcinomatosis from colon and rectal cancer:guidelines for current practice.Tumori 1997; 83:725-728
9[31]Deraco M,Rossi CR,Pennacchioli E,Guadagni S,Somers DC,Santoro N,Raspagliesi F,Kusamura S,Vaglini M.Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer:a phase Ⅱ clinical study.Tumori 2001; 87:120-126
